Neonicotinoid Poisoning and Management

Velmurugan Selvam¹, Shrikanth Srinivasan²

ABSTRACT
Neonicotinoids are a newer class of insecticides, which act on postsynaptic nicotinic acetylcholine esterase receptors. Its use is gradually increasing over recent years due to its better safety profile compared to other commonly used pesticides like organophosphates, organochlorides, carbamates, and pyrethroids. The better toxicological profile is attributed to more selectivity for insects compared to mammals and decreased penetration through the blood–brain barrier. Common symptoms of self-poisoning described are dizziness, hypertension, tachycardia, nausea, vomiting, eye irritation, dermatitis, and oral mucosal lesions. Mortality due to poisoning is less than 3%. Till date, there is no specific antidote for neonicotinoid poisoning and management of poisoning is symptomatic and supportive.

Keywords: Acute poisoning, Insecticide, Neonicotinoid.

INTRODUCTION
Acute pesticide poisoning is an important cause of intentional self-poisoning in India. The World Health Organization (WHO) estimates around 3,00,000 deaths per year due to pesticide poisoning in the Asia-pacific region.¹ Among various pesticides, organophosphates are the major cause of self-poisoning death in southern and central India² and aluminum phosphide is the major cause in some parts of northern India.³ Other pesticides used for self-poisoning are organochlorides, carbamates, and pyrethroids. Due to high mortality of these compounds, there has been a constant search for newer pesticides with a favorable safety profile.

Neonicotinoids are a newer class of insecticides with increasing usage in recent decades because of their favorable toxicological profile. Neonicotinoids have very high margin of safety because of specificity of the insecticides for nicotinic acetyl choline receptors (nAChRs) in insects than mammals combined with rapid metabolism and poor penetration to the blood–brain barrier. The mortality due to neonicotinoid poisoning is 0–2.9%,⁴,⁵ which is very much less than that of other pesticides.

CLASSIFICATION
Neonicotinoids are a newer class of pesticides used in the agricultural industry for crop protection, horticulture, and fleas control. In 1972, the first neonicotinoid nithiazine was developed but was never commercialized. Imidacloprid, a chloronicotinyl neonicotinoid, is the first agent in the group to be used as a commercial pesticide. Its use is gradually increasing over years and is currently one of the best-selling insecticides all over the world. Other members of this group are thiamethoxam, clothianidin, thiacloprid, acetamiprid, dinofuran, nitenpyram, imidaclothiz, flonicamid, sulfoxaflor, and cycloxaclid. The classification of this group is shown in Table 1.

MECHANISM OF ACTION
Neonicotinoids are neurotoxins that act as agonists in postsynaptic nAChRs of the nervous system mainly on the parasympathetic system and some of the sympathetic system. They bind irreversibly to the receptors that initially stimulate and then block Na⁺/K⁺ channels leading to blockade of transmission of nervous influx.
Neonicotinoid Poisoning and Management

Indian Journal of Critical Care Medicine, December 2019;23 (Suppl 4)

**Table 1: Classification of neonicotinoids**

| Generation of neonicotinoids | Type of neonicotinoid |
|-----------------------------|----------------------|
| First-generation neonicotinoids | Imidacloprid |
|                              | Nitenpyram |
|                              | Acetamiprid |
|                              | Thiaclopid |
| Second-generation neonicotinoids | Thiamethoxam |
|                              | Clothianidin |
| Third-generation neonicotinoids | Dinofuran |
|                              | Sulfoxaflor |
|                              | Cycloxaprid |

**Table 2: Mechanism of action of major insecticides**

| Class             | Target            | Selectivity factor |
|-------------------|-------------------|--------------------|
| Neonicotinoids    | nACHR*            | 456                |
| Organophosphates  | AChE**            | 33                 |
| Carbamates        | AChE**            | 16                 |
| Organochlorines   | Na⁺ or Cl⁻ channel | 91             |
| Pyrethroids       | Na⁺ channel       | 4,500              |

*Nicotinic acetyl choline receptors
**Acetylcholine esterase

Data from ref. 6

progressed after high doses. Cytochrome P450 isoenzymes play an important role in the metabolism of imidacloprid. Two pathways have been identified by which imidacloprid is metabolized. One is hydroxylation and desaturation to S-hydroxyimidacloprid and imidacloprid olefin by CYP 3A4 isoenzymes and the second is the nitroimine reduction pathway to yield nitroso guanidine, aminoguanidine, and urea imidacloprid by CYP 1A2, 2B6, 2D6, and 2E1 isoenzymes. So, concomitant use of cytochrome enzyme inhibitors increases the toxicity. There is no distribution to fat-rich tissues and penetration through the blood–brain barrier is minimal. They are not accumulated in the body and undergo complete elimination in 48 hours.

**Clinical Symptoms and Presentation**

Clinical symptoms of neonicotinoid poisoning are less severe in humans because of their decreased affinity for human nicotinic receptors, rapid metabolism by cytochrome enzymes, and their limited ability to cross the blood–brain barrier. Clinical features are better described for imidacloprid that is the most commonly used insecticide in the neonicotinoid group. One of the large reports of neonicotinoid symptomatology is from the Texas Poison Center, which included 1,142 exposures during the period 2000–2012. The main symptoms described in the study after exposure are dizziness, hypertension, tachycardia, nausea, vomiting, eye irritation, dermatitis, oral mucosal lesions. Neonicotinoid initially stimulates the nicotinic receptors in the nervous system followed by blockade of nerve transmission by continued stimulation leading to fatigue. This effect leads to initial symptoms like headache, agitation, fasciculations, seizures followed by disorientation, drowsiness, decreased muscle tone, and coma. Stimulation of receptors in the autonomic nervous system leads to tachycardia, hypertension, diaphoresis, and mydriasis. Gastrointestinal symptoms like nausea, vomiting, abdominal pain, and corrosive damage to orogastric mucosa are common. Severe clinical features like respiratory failure, ventricular fibrillation, myocardial ischemia due to coronary vasospasm, acute renal failure, and rhabdomyolysis have been reported. Concomitant intoxication of imidacloprid with alcohol leading to multiorgan failure and death has been reported in a case report. Solvents used in the insecticide also play a role in poisoning symptoms. The most commonly used solvent in neonicotinoid is N-methylpyrrolidone. Ingestion of a large amount of this solvent causes abdominal pain, oral ulceration, nausea, vomiting, dysphagia, and odynophagia.

**Management**

Management of acute neonicotinoid poisoning is mainly symptomatic and supportive. Dermal and mucosal decontamination and removal of contaminated clothes should be done immediately as these compounds undergo absorption by the dermal and inhalational route. Gastric decontamination should be considered after large volume ingestion (over 100 mL) and if the patient presents within 1 hour. Gastric lavage and activated charcoal should be avoided if corrosive damage to the orogastric mucosa is suspected due to the solvent. Assisted ventilation and hemodynamic support should be considered in the presence of hypotension, poor Glasgow coma scale (GCS<8), hypoventilation, or respiratory distress. In case of hoarseness of voice or stridor, the airway should be secured as early as possible and endoscopic evaluation of the vocal cords and airway mucosa should be done.

There is no specific antidote for neonicotinoid agents. Neonicotinoid poisoning can sometimes present with muscarinic clinical features such as excessive salivation, lacrimation, urination, bronchorrhea, miosis, and bradycardia similar to organophosphates. Atropine and oximes may be administered inadvertently because of the clinical presentation. Oximes are ineffective or sometimes can cause adverse effects when administered in neonicotinoid poisoning. Oximes have weak acetyl choline esterase inhibiting activity and can cause tachycardia, hypertension, and other nicotinic symptoms if administered in the absence of organophosphate compounds. However, careful use of atropine may be justified if patients present with severe life-threatening clinical features like severe bronchorrhea leading to airway compromise or severe bradycardia.

**Conclusion**

Neonicotinoids are a newer class of insecticide and their use is increasing over recent years. Because of their wider application, number of poisoning is also increasing over the recent decades. Although neonicotinoids appear to be less toxic compared to other insecticides, sometimes severe complications like respiratory failure, ventricular fibrillation, and death have been reported. There is no specific antidote and management at present is supportive and symptomatic. Available evidence for toxicokinetics of neonicotinoids and management of poisoning is mainly based on animal studies, case reports, and case series. More research is required for evidence-based management of neonicotinoid poisoning.

**References**

1. Jeyarathnam J. Acute pesticide poisoning: a major global health problem. World Heal Stat Q 1990;43(3):139–144.
2. Batra AK, Keoliya AN, Jadhav GU. Poisoning: an unnatural cause of morbidity and mortality in rural India. J Assoc Physicians India 2003;51:955–959.

3. Singh D, Jit I, Tyagi S. Changing trends in acute poisoning in Chandigarh zone: a 25-year autopsy experience from a tertiary care hospital in northern India. Am J Forensic Med Pathol 1999;20(2):203–210. DOI: 10.1097/00000433-199906000-00019.

4. Phua DH, Lin CC, Wu ML, Deng JF, Yang CC. Neonicotinoid insecticides: an emerging cause of acute pesticide poisoning. Clin Toxicol 2009;47(4):336–341. DOI: 10.1080/15563650802644533.

5. Mohamed F, Gawarammana I, Robertson TA, Roberts MS, Palangasinghe C, Zawahir S, et al. Acute human self-poisoning with imidacloprid compound: a neonicotinoid insecticide. PLoS One 2009;4(4):e5127. DOI: 10.1371/journal.pone.0005127.

6. Tomizawa M, Casida JE. Neonicotinoid insecticide toxicology: mechanisms of selective action. Annu Rev Pharmacol Toxicol 2005;45(1):247–268. DOI: 10.1146/annurev.pharmtox.45.120403.095930.

7. Wang X, Anadón A, Wu Q, Qiao F, Ares I, Martinez-Larrañaga MR, et al. Mechanism of neonicotinoid toxicity: impact on oxidative stress and metabolism. Annu Rev Pharmacol Toxicol 2018;58(1):471–507. DOI: 10.1146/annurev-pharmtox-010617-052429.

8. Forrester MB. Neonicotinoid insecticide exposures reported to six poison centers in Texas. Hum Exp Toxicol 2014;33(6):568–573. DOI: 10.1177/0960372714522500.

9. David D, George IA, Peter JV. Toxicology of the newer neonicotinoid insecticides: imidacloprid poisoning in a human. Clin Toxicol 2007;45(5):485–486. DOI: 10.1080/15563650701338229.

10. Lin PC, Lin HJ, Liao YY, Guo HR, Chen KT. Acute poisoning with neonicotinoid insecticides: a case report and literature review. Basic Clin Pharmacol Toxicol 2013;112(4):282–286. DOI: 10.1111/bcpt.12027.

11. Karatas AD. Severe central nervous system depression in a patient with acute imidacloprid poisoning. Am J Emerg Med 2009;27(9):1171. e5–1171.e7. DOI: 10.1016/j.ajem.2009.01.006.

12. Kumar A, Verma A, Kumar A. Accidental human poisoning with a neonicotinoid insecticide, imidacloprid: a rare case report from rural India with a brief review of literature. Egypt J Forensic Sci 2013;3(4):123–126. DOI: 10.1016/j.ejfs.2013.05.002.

13. Iyyadurai R, George IA, Peter JV. Imidacloprid poisoning-newer insecticide and fatal toxicity. J Med Toxicol 2010;6(1):77–78. DOI: 10.1007/s13181-010-0041-6.

14. Yeh IJ, Lin TJ, Hwang DY. Acute multiple organ failure with imidacloprid and alcohol ingestion. Am J Emerg Med 2010;28(2):255.e1–255.e3. DOI: 10.1016/j.ajem.2009.05.006.

15. Hung YM, Lin SL, Chou KJ, Chung HM. Imidacloprid-n-methyl pyrrolidone insecticides poisoning mimicking cholinergic syndrome (abstract). Clin Toxicol (Phila) 2006;44:771–772.